Bristol-Myers Squibb (BMY) versus Its Peers Head-To-Head Review
Bristol-Myers Squibb (NYSE: BMY) is one of 113 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Bristol-Myers Squibb to related businesses based on the strength of its dividends, earnings, institutional ownership, valuation, profitability, analyst recommendations and risk.
Risk & Volatility
Bristol-Myers Squibb has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Bristol-Myers Squibb’s rivals have a beta of 0.87, indicating that their average stock price is 13% less volatile than the S&P 500.
Institutional & Insider Ownership
68.9% of Bristol-Myers Squibb shares are owned by institutional investors. Comparatively, 44.0% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 0.2% of Bristol-Myers Squibb shares are owned by company insiders. Comparatively, 12.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Bristol-Myers Squibb and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Bristol-Myers Squibb||$20.24 billion||$6.01 billion||23.48|
|Bristol-Myers Squibb Competitors||$7.79 billion||$2.46 billion||0.03|
Bristol-Myers Squibb has higher revenue and earnings than its rivals. Bristol-Myers Squibb is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Bristol-Myers Squibb pays an annual dividend of $1.56 per share and has a dividend yield of 2.4%. Bristol-Myers Squibb pays out 56.7% of its earnings in the form of a dividend. As a group, “Pharmaceuticals” companies pay a dividend yield of 2.3% and pay out 82.4% of their earnings in the form of a dividend. Bristol-Myers Squibb has raised its dividend for 7 consecutive years. Bristol-Myers Squibb is clearly a better dividend stock than its rivals, given its higher yield and lower payout ratio.
This table compares Bristol-Myers Squibb and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Bristol-Myers Squibb Competitors||-3,194.33%||-54.63%||-8.65%|
This is a summary of recent recommendations for Bristol-Myers Squibb and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Bristol-Myers Squibb Competitors||951||3817||6055||164||2.49|
Bristol-Myers Squibb currently has a consensus price target of $61.54, indicating a potential downside of 4.68%. As a group, “Pharmaceuticals” companies have a potential upside of 22.71%. Given Bristol-Myers Squibb’s rivals stronger consensus rating and higher probable upside, analysts clearly believe Bristol-Myers Squibb has less favorable growth aspects than its rivals.
Bristol-Myers Squibb beats its rivals on 10 of the 15 factors compared.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company’s products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.